Appendix 4E & 2018 Full Year Statutory Accounts
Filed with ASX · · 82 pages · English
The higher loss after tax for FY2018 of A$12,746,020 compared to A$9,367,206 for FY2017, was mainly due to non-cash expenses. The operating cash flows reduced year on year from A$8.5m in FY2017 to A$7.8 in FY2018. For other details of the current year results, refer to the Review of Operations. 3. NTA backing 4. Dividends Current period There were no dividends paid or declared during the current f
Story so far
Earlier from Immutep
- TACTI-mel Patient Recruitment Complete & Operational Update
- Immutep receives IND approval from US FDA for IMP321
- Immutep submits IND application with FDA
- Mid-point of patient enrolment reached in AIPAC trial
- Webcast slides for TACTI-mel clinical trial data
Later from Immutep
- Progress towards clinical development of IMP761
- Immutep enters into collaboration with Pfizer & Merck KGaA
- Positive interim TACTI-mel data presented at SITC
- Immutep granted European patent for IMP321
- European patent granted for IMP321 & antibody combinations
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep